IPN 60300
Alternative Names: FS-001; IPN-60300Latest Information Update: 03 Jul 2026
At a glance
- Originator Foreseen Biotechnology
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 30 Jun 2026 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in France (Parenteral) (NCT07213817)
- 22 Apr 2026 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical trials in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 17 Apr 2026 Pharmacodynamics data from preclinical trial in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)